elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

23-Sep-2005
Elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company. Taapken (40), previously spent 3 years as a Partner in the Life Science team of DVC, Deutsche Venture Capital, and was a member of the supervisory board of elbion AG. He has resigned from DVC, and has also stepped down from his position as a supervisory board member of the company, to join elbion's management board. Prior to his position at DVC, Thomas Taapken worked for 8 years at Sanofi-Aventis in the areas of research, corporate development and venture capital. In his last position he held responsibility for the corporate venture capital activities of the group. Dr. Taapken holds a PhD in chemistry from the Technical University of Berlin.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances